Cumberland Pharmaceuticals Inc. Q3 2025 Earnings Recap

CPIX Q3 2025 November 5, 2025

Get alerts when CPIX reports next quarter

Cumberland Pharmaceuticals reported solid financial performance in Q3 2025, marked by strategic commercial partnerships and a focus on expanding its product portfolio. The company's revenue growth and continued operational advancements reinforce optimistic future projections.

Market Reaction

1-Day -12.41%

5-Day -25.56%

30-Day -15.04%

See CPIX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Entered a joint commercialization agreement with RedHill Biopharma for Talicia, now a first-line therapy for H. pylori infections; projected 2024 net sales of $8 million.
Third quarter revenues reached $8.3 million, with a 12% increase year-to-date despite shipment delays.
Positive cash flow from operations of nearly $5 million year-to-date, indicating robust financial health amid ongoing investments.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CPIX on AllInvestView.